Latest News & Features
Americas
Genetic sequencing company Illumina is set to pay $8 billion for Grail, a cancer detection company that was spun out of Illumina four years ago. 23 September 2020
Americas
Bristol Myers Squibb and Celgene have settled their patent litigation with Dr Reddy’s over a generic version of cancer drug Revlimid. 22 September 2020
Americas
Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer. 22 September 2020
Biotechnology
The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds. 21 September 2020
Americas
Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard. 21 September 2020
Biotechnology
In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court. 21 September 2020
article
Innovations in the life sciences have dramatically advanced the quality of health care in the United States. In recent years, diagnostic tests and drug therapies that once seemed beyond our grasp have now become the standard of care in this country. 17 September 2020
Big Pharma
The European Patent Office has invalidated and revoked a patent related to Teva’s
multiple sclerosis drug Copaxone, in a win for Mylan. 17 September 2020
article
Members of the legal profession have been developing diversity programmes and policies to promote more inclusivity in the legal field for years, but recent events have led leadership teams to re-evaluate their diversity programmes and renew their efforts to build a more diverse legal profession. 16 September 2020
Americas
Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin. 16 September 2020